공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 죽종제거술 기기 시장 : 제품별, 용도별, 최종사용자별, 지역별 - 성장, 동향, 예측

Atherectomy Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 635925
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


세계의 죽종제거술 기기 시장 : 제품별, 용도별, 최종사용자별, 지역별 - 성장, 동향, 예측 Atherectomy Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 죽종제거술 기기(Atherectomy Devices) 시장을 조사했으며, 시장 개요, 제품별·용도별·최종사용자별·지역별 동향, 시장 진출기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 추론

제5장 시장 개요

  • 현재의 시장 시나리오
  • Porter's Five Forces 분석

제6장 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 저해요인

제7장 시장 세분화

  • 제품별
    • 방향성 죽종제거술 시스템
    • 궤도성 죽종제거술 시스템
    • 광절제(레이저) 죽종제거술 시스템
    • 회전성 죽종제거술 시스템
  • 용도별
    • 말초혈관
    • 심혈관
    • 신경혈관
  • 최종사용자별
    • 병원 및 외과센터
    • 외래 수술 센터
    • 연구기관 및 학술기관
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타

제8장 경쟁 환경

  • 인수합병(M&A) 분석
  • 협정, 협업, 제휴
  • 신제품 출시

제9장 주요 시장 진출기업

  • Abbott Laboratories
  • Avinger
  • B. Braun Group
  • Biomerics
  • Biotronik
  • Boston Scientific
  • C.R. Bard
  • Cardinal Health
  • Cardiovascular Systems
  • Koninklijke Philips
  • Medtronic
  • Minnetronix Inc.
  • RA Medical Systems
  • Straub Medical
  • Terumo Corporation

제10장 시장 전망

LSH 18.05.23

The atherectomy devices market is projected to register a CAGR of about 6.03%, during the forecast period with a revenue of approximately USD 790.41 million in 2020 and is expected to increase to USD 1,118.57 million by 2026.

The market like many other markets has been impacted by the pandemic. Various cardiovascular procedures and non-essential treatments have been postponed. Additionally, non-COVID-19-related researches are being postponed by various companies, which is leading to delayed product launches. Some disruptions in sourcing raw materials from impacted countries, such as China, were also observed in early 2020, but such disruptions are unlikely to have a significant impact going forward. However, as earlier restrictions are now easing in several countries, the market growth may also resume.​

The market for Atherectomy devices is majorly driven by the rising preference for minimally invasive surgeries. In minimally invasive surgery, doctors use a variety of methods to operate with minimal damage to the body, as opposed to the traditional open surgery method. Generally, minimally invasive surgery is associated with less pain, a shorter hospital stay, and fewer complications. Atherectomy is a minimally invasive procedure generally used to treat arteries. The demand for this surgery is increasing at a very high rate due to several factors that include - less pain, shorter hospital stay, less scarring, less tissue injury, and a higher accuracy rate. Additionally, other factors, such as continuous product development and commercialization, favorable medical reimbursement scenario in mature markets, and strengthening distribution channels of major product manufacturers is expected to aid the growth of the atherectomy devices market.

As surgical specialists are one of the primary users of minimally invasive devices, many countries are facing a shortage of talented healthcare professionals. Due to this shortage, patients have to (reluctantly) undergo conventional procedures. These factors are limiting the scope of this market. Hospitals with high patient enrollments are also facing this issue. Despite possessing the purchasing power, these hospitals cannot install such devices. In many countries, the rural population forms a significant part of the total population.

According to Roma Pahwa, in the article published in 2020, in the United States, about 610,000 people die of heart disease every year that is 1 of every 4 deaths. Coronary heart disease is the leading cause of death in the region killing over 370,000 people yearly. On average, about 735,000 Americans have a heart attack every year. The growing number of patients increases the demand for the devices.

The shortage of healthcare professionals is more acute in rural regions, where most of the healthcare centers are owned by the state. Government schemes are funding heavily to improve the status of health in rural regions. However, the minimally invasive devices category is unable to utilize this opportunity due to the shortage of experienced professionals who possess the expertise to operate such devices. This is expected to slow down the growth of the market studied along with other factors, such as stringent regulations.

Key Market Trends

Directional Atherectomy Segment Holds a Major Share in the Market

The directional atherectomy segment of the market is expected to witness significant growth in the forecast years over other products as it offers certain advantages such as low treatment cost, improved efficiency, etc. The increasing adoption of minimally invasive atherectomy procedures will boost the demand for atherectomy devices.

Plaque removal by directional atherectomy may produce an angiographic result that is superior to that obtainable by percutaneous transluminal coronary angioplasty, particularly for lesions that are eccentric, ostial, restenotic, or associated with intraluminal thrombus.

Various clinical trials to prove the efficacy of the device also contributes to the high demand. Trials such as DEFINITIVE LE (determination of the effectiveness of the SilverHawk peripheral plaque excision system for infrainguinal vessels/lower extremities treatment) and EASE (Endovascular Atherectomy Safety and Effectiveness) displayed a success rate of more than 90% assuring the effectiveness of the concerned devices. Such factors, along with the global presence of medical devices across developed and emerging markets, drive the demand of directional atherectomy devices.

North America is expected to dominate the Atherectomy Devices Market

North America is expected to have the largest share of the market. Factors, such as increasing availability of reimbursements for atherectomy systems, adoption of atherectomy systems among medical professionals, the large patient population of peripheral & coronary artery diseases, and an increasing number of clinical trials (that aim to evaluate the therapeutic efficacy of atherectomy systems in specific disease treatment) are driving the growth of the North American atherectomy devices market.

As per the American Heart Association, 2018, age-related cognitive impairment due to Alzheimer's disease, vascular dysfunction, or other causes is also growing exponentially, leading to the growing rate of hospitalizations and requiring vascular devices-linked treatments, thereby, increasing healthcare expenditure related to heart disease.

For instance, it is estimated that in 2019, there were about 53.340 million (16.2%) population aged 65 or older in the United States. This number is projected to reach 70.842 million (20.3%) in 2030. The elderly population is expected to increase in the near future, and this population is more prone to chronic conditions like cardiovascular diseases, which is likely to impact the market positively.

Suitable reimbursement scenario and a high number of FDA approved devices are the key reasons for this dominance. For instance, in April 2019, Avinger, Inc. received 510(k) clearance from the FDA for Pantheris SV (Small Vessel) image guided atherectomy system. A product line extension of its Lumivascular image-guided atherectomy platform is expected the Pantheris market by 50% thereby increasing its share in the atherectomy devices market.

Competitive Landscape

The Atherectomy Devices market is moderately competitive and many of the global players are into the market. For instance - Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific, C.R. Bard, Cardinal Health, Inc., Koninklijke Philips N.V., Medtronic PLC, Terumo Corporation, etc. are providing these products across the globe.For instance, in January 2017, Medtronic plc received CE mark approval for its HawkOne directional atherectomy system. The new HawkOne 6 French (6F) system for treating patients with PAD provides easy to use treatment option with a single device.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Continuous Product Development and Commercialisation
    • 4.2.2 Favourable Medical Reimbursement Scenario in Mature Markets
    • 4.2.3 Rising Demand for Minimally Invasive Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Lack of Well-trained Surgeons
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Directional Atherectomy Systems
    • 5.1.2 Orbital Atherectomy Systems
    • 5.1.3 Photo-Ablative (Laser) Atherectomy Systems
    • 5.1.4 Rotational Atherectomy Systems
  • 5.2 By Application
    • 5.2.1 Peripheral Vascular Applications
    • 5.2.2 Cardiovascular Applications
    • 5.2.3 Neurovascular Applications
  • 5.3 By End User
    • 5.3.1 Hospitals & Surgical Centers
    • 5.3.2 Ambulatory Care Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (By Product, By Application, and By End User)
      • 5.4.1.2 Canada (By Product, By Application, and By End User)
      • 5.4.1.3 Mexico (By Product, By Application, and By End User)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (By Product, By Application, and By End User)
      • 5.4.2.2 United Kingdom (By Product, By Application, and By End User)
      • 5.4.2.3 France (By Product, By Application, and By End User)
      • 5.4.2.4 Italy (By Product, By Application, and By End User)
      • 5.4.2.5 Spain (By Product, By Application, and By End User)
      • 5.4.2.6 Rest of Europe (By Product, By Application, and By End User)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (By Product, By Application, and By End User)
      • 5.4.3.2 Japan (By Product, By Application, and By End User)
      • 5.4.3.3 India (By Product, By Application, and By End User)
      • 5.4.3.4 Australia (By Product, By Application, and By End User)
      • 5.4.3.5 South Korea (By Product, By Application, and By End User)
      • 5.4.3.6 Rest of Asia-Pacific (By Product, By Application, and By End User)
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC (By Product, By Application, and By End User)
      • 5.4.4.2 South Africa (By Product, By Application, and By End User)
      • 5.4.4.3 Rest of Middle East and Africa (By Product, By Application, and By End User)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (By Product, By Application, and By End User)
      • 5.4.5.2 Argentina (By Product, By Application, and By End User)
      • 5.4.5.3 Rest of South America (By Product, By Application, and By End User)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 B. Braun Melsungen AG
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 C.R. Bard (Becton, Dickinson and Company)
    • 6.1.5 Cardinal Health, Inc.
    • 6.1.6 Koninklijke Philips N.V.
    • 6.1.7 Medtronic
    • 6.1.8 RA Medical Systems
    • 6.1.9 Straub Medical
    • 6.1.10 Terumo Corporation
    • 6.1.11 Cardiovascular Systems Inc.
    • 6.1.12 Minnetronix, Inc.
    • 6.1.13 Avinger Inc.
    • 6.1.14 Biomerics LLC.
    • 6.1.15 AngioDynamics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q